

## Drugs and Nutritional Supplements in the Therapy of Interstitial Pneumonia Complications in Post-COVID Fibrosis

Maria Chaneva<sup>1</sup>, Petar Atanasov<sup>1</sup>, Danka Obreshkova<sup>1</sup>, Valentin Dimitrov<sup>1</sup>, Christo Tzachev<sup>2</sup>, Adel Ibrahim<sup>3</sup>, Stefka Ivanova<sup>4</sup>

<sup>1</sup>University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, Sofia, Bulgaria

<sup>2</sup>Sofia University St. Kliment Ohridski”, Faculty of Chemistry and Pharmacy, Sofia, Bulgaria

<sup>3</sup>Pharmacy of Hospital UMHATEM, University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I.Pirogov”, Sofia, Bulgaria

<sup>4</sup>Bulgarian Pharmaceutical Science Society, Sofia, Bulgaria

DOI: <https://doi.org/10.36347/sajp.2026.v15i01.003> | Received:21.11.2025| Accepted:27.01.2026| Published:31.01.2026

\*Corresponding author:Stefka Ivanova

Bulgarian Pharmaceutical Science Society, Sofia, Bulgaria

### Abstract

### Review Article

Increased collagen synthesis is the cause of the disease fibrosis. Factors contributing to the development of fibrosis include chronic inflammation, infections, oxidative stress, autoimmune diseases, physical injuries, surgical procedures, long-term exposure to toxins, radiation therapy. Types of fibrosis are pulmonary, cardiac, renal, hepatic, intestinal, skin, skeletal muscle fibrosis. The aim of current study is the estimation of the potential beneficial effect of drugs and nutritional supplements in the therapy of Interstitial Pneumonia complication in Post-COVID Fibrosis. The beneficial effect is shown of application of enzyme therapy using the product Fibrozim including the enzymes Serrazime and Bromelain and antioxidants Quercetin and Curcumin.

**Keywords:** Post-COVID Fibrosis, Interstitial Pneumonia, Serrazime, Bromelain, Quercetin.

Copyright © 2026 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

## INTRODUCTION

### I. Factors contributing to the development of fibrosis [1].

Fibrosis is a tissue degeneration, characterized with an excessive accumulation of connective tissue components in the extracellular matrix (ECM) area of tissues [1].

#### Factors contributing to the development of fibrosis include:

1. Chronic inflammation caused by conditions such as chronic liver inflammation (chronic hepatitis) or inflammatory bowel disease
2. Long-term infections such as tuberculosis
3. Oxidative stress [2]
4. Autoimmune diseases: rheumatoid arthritis or lupus are conditions in which the immune system mistakenly attacks its own tissues and fibrous tissue builds up.
5. Physical injuries
6. Surgical procedures
7. Long-term exposure to toxins, drugs or environmental pollutants – fibrosis of the lungs

and liver.

8. Radiation therapy: can damage healthy tissues, causing fibrosis as a side effect.

### II. Pathogenesis of fibrosis

The basic components of fibrotic tissue are collagen type I and III [1]. Disruption of collagen synthesis leads to disruption of the normal structure of tissues and organs. Collagen is the main structural protein in connective tissue, constituting 25% to 35% of the extracellular matrix. Collagen is composed of amino acids coiled together to form triple helices into elongated fibrils. It is found primarily in fibrous tissues such as tendons and skin. Common to all fibrotic diseases is the activation of myofibroblasts (a type of connective tissue cell) that produce extracellular matrix (the collection of substances surrounding cells in a given tissue type), which are key mediators of fibrous tissue remodeling [1].

The fibrosis process is associated with chronic inflammation, transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) signaling [3] and oxidative stress [2]. In the

pathogenesis of fibrosis, oxidative stress plays a crucial role [4] by promoting inflammation due to increasing the production of cytokines and growth factor TGF- $\beta$  [5], and stimulation of myofibroblast differentiation and fibrogenesis. Pro-fibrotic factors and cytokines are among the mediators of fibrosis in lungs [6], heart [7], kidney [8] and liver [9].

### III. Types of fibrosis

#### 1. Pulmonary fibrosis

Pulmonary Fibrosis is connected with high levels of pro-inflammatory cytokines, such as interleukines [10].

#### 2. Cardiac fibrosis

Cardiac fibrosis is caused by unsuitable fibroblast proliferation. Cardiac fibrosis affects the heart's ability to pump blood effectively. Angiotensin II stimulates collagen-secreting myofibroblasts via increasing fibroblast proliferation and differentiation. Transforming growth factor beta (TGF- $\beta$ ) mediates cardiac fibrosis [11] increasing the cardiac myofibroblasts production of fibronectin, and interstitial collagens [12].

#### 3. Kidney fibrosis

Kidney fibrosis is a characteristic of the development of renal lesions and acute kidney injury contributes to renal fibrosis [8]. The renin-angiotensin-aldosterone system plays a potential role in epithelial-to-mesenchymal transition-induced renal abnormalities [13].

#### 4. Chronic liver fibrosis

Chronic liver fibrosis is caused by chronic liver diseases such as hepatitis and is connected with cytokine release such as transforming growth factor-beta (TGF- $\beta$ ), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), tumor necrosis factor-alpha (TNF- $\alpha$ ) [14].

#### 5. Intestinal fibrosis [15]

#### 6. Skeletal muscle fibrosis [16]

7. **Skin fibrosis:** it is observed in cases such as scleredermis [17].

### IV. Pulmonary fibrosis

Pulmonary fibrosis is the process of replacing normal lung tissue with fibrous (connective) tissue, which leads to impaired lung function. Fibrosis is a dynamic process that occurs in phases. The local focus of sclerosis, in which a defect or focal necrosis is replaced, is called acicatrix. This makes it difficult to transport oxygen in the blood and can lead to severe respiratory problems. The process develops gradually, and at first there may be no pronounced symptoms, but as the disease progresses, the symptoms become more and more obvious. Oxidative stress is an important factor for the development of pulmonary fibrosis [2].

### V. Types of pulmonary fibrosis [14]

#### 1. Idiopathic Pulmonary Fibrosis (IPF)

This is the most common type of pulmonary fibrosis, in which the cause of the disease is unknown. IPF develops slowly and can lead to serious lung damage. High levels of pro-inflammatory cytokines, such as interleukines IL-1, IL-8, and IL-18 are produced in the development of the disease [10]. Fibroblast transforming growth factor- $\beta$  binding protein-2 [6] regulates lung fibroblast-to-myofibroblast differentiation in pulmonary fibrosis [3].

#### 2. Pulmonary fibrosis due to inhalation of harmful substances

Inhalation of toxic chemicals, dust, gases, or other harmful substances, such as asbestos, can cause the development of pulmonary fibrosis. This condition is common in people who work in hazardous industries [10].

#### 3. Pulmonary fibrosis in chronic diseases

Some chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and sarcoidosis can cause pulmonary fibrosis as part of their complications [10].

#### 4. Fibrosis after infection

Some lung infections, such as pneumonia, can lead to permanent tissue damage and the development of fibrosis [10].

### VI. Treatment of pulmonary fibrosis [14]

Treatment of pulmonary fibrosis includes:

#### 1. Drug treatment

#### 2. Oxygen therapy

In advanced cases, patients may need oxygen therapy to assist breathing and improve blood oxygen levels.

#### 3. Lung physiotherapy

Physiotherapy can help improve lung function and relieve symptoms of shortness of breath and cough.

#### 4. Lung transplantation

When the disease is in an advanced stage and other treatment methods are not effective, a lung transplant may be necessary.

### VII. Drug treatment of pulmonary fibrosis

Drug treatment of pulmonary fibrosis includes [18]:

#### 1. Corticosteroids

For fibrosis associated with inflammation, corticosteroids may be prescribed. They help to reduce the inflammation in the lungs and relieve symptoms such as cough and shortness of breath [19].

#### 2. Antifibrotic drugs

Pirafenidone and Nintedanib are approved for the treatment of Idiopathic Pulmonary Fibrosis and slow the progression of the disease by reducing the formation of scar tissue in the lungs.

### 3. Immunosuppressive drugs

For fibrosis caused by autoimmune diseases such as rheumatoid arthritis or sarcoidosis, immunosuppressive drugs may be used due to they suppress the activity of the immune system and help to prevent damage of lung tissue.

### 4. Antioxidants – Vitamin C and Vitamin E

Reactive oxygen species play role in development of fibrosis [20]. Vitamin C is a powerful antioxidant that plays a role in cell repair processes and is important for maintaining healthy connective tissue, which is a concern in pulmonary fibrosis. Vitamin E has antioxidant properties and may help to reduce the oxidative stress [21].

### 5. Omega-3 fatty acids

Omega-3 fatty acids, which are found in fish oil, flaxseed, and chia, are known for their anti-inflammatory properties. They can be very beneficial for patients with pulmonary fibrosis, as inflammation is a major factor in the development of this disease.

### 6. Glutathione

Glutathione is an important antioxidant that is produced by the body and plays an important role in protecting cells from oxidative stress and toxins. Low levels of glutathione can accelerate the development of lung diseases such as fibrosis, as the organs cannot effectively protect themselves from damage [21].

### 7. Curcumin

Curcumin, the main active ingredient in turmeric, is known for its anti-inflammatory and antioxidant properties [22]. It may also be extremely beneficial as an antioxidant for people with pulmonary fibrosis, as inflammation plays a key role in the development and progression of the disease [23].

### 8. Magnesium

Magnesium is an important mineral that plays a role in many physiological processes, including regulating muscle contractions, which is important for the proper function of the respiratory system. People with pulmonary fibrosis often experience muscle spasms and chest tightness, which can be relieved by magnesium supplements.

## VIII. Post-COVID Fibrosis

Progressive pulmonary fibrosis is the final stage of damage caused by a heterogeneous group of chronic interstitial lung diseases, particularly Acute Interstitial Pneumonia (AIP) caused by the COVID virus. Pulmonary fibrosis is a condition characterized by the abnormal accumulation of connective (fibrous)

tissue in the lungs. This process primarily affects the interstitium – the supporting fine connective tissue and the space between the alveoli and blood vessels in the lung.

### 1. Similarities between Post-COVID Fibrosis and Idiopathic Pulmonary Fibrosis (IPF)

The clinical and imaging features of Post-COVID Fibrosis are often similar to those of Idiopathic Pulmonary Fibrosis (IPF). Progressive dyspnea (shortness of breath) and nonproductive cough, which are hallmarks of IPF, may also be seen in patients after COVID-19. Computer tomography (CT) findings of reticular induration, consolidation, traction bronchiectasis, and even "honeycombing". In both cases, there is deregulation of the repair processes after injury, leading to uncontrolled fibrosis.

### 2. Differences (the key) between Post-COVID Fibrosis and Idiopathic Pulmonary Fibrosis (IPF).

Post-COVID fibrosis requires a new diagnostic and therapeutic approach. The post-COVID-19 patient has a clear, identifiable cause (viral infection), while IPF is by definition idiopathic (of unknown cause). This may lead to a different response to therapy. Many patients with post-COVID fibrosis initially had organizing pneumonia (OP) or acute respiratory distress syndrome (ARDS), which is different from the gradual onset of IPF.

### 3. Potential for regression of Post-COVID Fibrosis.

There is evidence that in some Post-COVID Fibrosis, especially in the early stages, fibrotic changes may regress or stop progressing more effectively than in IPF. This necessitates a different therapeutic window. COVID creates a new type of patient that is different from the classic IPF patient. In post-IPF fibrosis, the etiology is known.

### Diagnosis is less about finding a cause and more about:

1. Assessing disease progression.
2. Excluding concomitant autoimmune diseases provoked by the virus.

### 4. Treatment of Post-COVID Fibrosis.

Treatment of Post-COVID Fibrosis include corticosteroids, antifibrotic drugs, enzyme therapy [18].

#### 4.1. Corticosteroids.

Corticosteroids are used empirically in the subacute phase (up to 6 months) to control inflammation. Long-term use is dangerous and should be avoided. A rapid response is sought in the active phase, but they are stopped quickly to avoid the complications of prolonged immunosuppression. Respiratory diseases, such as chronic obstructive pulmonary disease, asthma, and pneumonia, are associated with significant morbidity and mortality [24]. In patients with acute exacerbation of idiopathic

pulmonary fibrosis early corticosteroid treatment is important [25].

Systemic corticosteroid drugs are commonused in several respiratory diseases [26], such as COVID-19 [27] pneumonia, severe community-acquired pneumonia, ARDS acute respiratory distress syndrome: [28, 29], and asthma [30].

In patients with acute respiratory distress syndrome after application of corticosteroids, a decreased mortality has been observed [31].

Severe forms of COVID-19 are attributed to an inflammatory cytokine storm and corticosteroids use could have the potential to decrease upregulated inflammatory response [24]. The RECOVERY study has shown the role of corticosteroids: in severe COVID-19: in the group of 2104 patients treated with 6 mg orally or intravenously dexamethasone once daily for up to 10 days, a significantly lower mortality has been reported [32].

#### 4.2. Antifibrotic drugs

The lungs are the primary target of infection. Coronavirus disease 19 (COVID-19), caused by the severe acute respiratory syndrome-virus 2 (SARS-CoV-2). Antifibrotic drugs are not routine treatment for all post-COVID patients, but are reserved for those whose condition worsens after 1 year of diagnosis [33]. Antifibrotics in pulmonary fibrosis [34] in post-COVID-19-induced severe pneumonia [35] are Nintedanib [35,36] and Pirfenidone [35,37]. Antifibrotics Pirfenidone and Nintedanib are used only in cases of proven progression and lack of regression after a thorough assessment of functional abnormalities. Nintedanib in the treatment of idiopathic pulmonary fibrosis blocks profibrotic signalling [36].

Pirfenidone is an anti-fibrotic drug approved for the treatment of patients with Idiopathic Pulmonary Fibrosis, the mechanism of action is based on the suppression of pro-fibrotic and pro-inflammatory signalling pathways as inhibition of TNF- $\alpha$ , TGF- $\beta$ 1, platelet-derived growth factor and collagen deposition [38]. Due to anti-inflammatory and antifibrotic properties Pirfenidone can be effective against COVID-19 infection [39, 40].

#### 4.3. Enzyme therapy with Serrazime and Bromelain

In treatment of post-COVID fibrosis are applied natural components, such as enzymes (Serrazime, Bromelain) and antioxidants as Quercetin and Curcumin. Proteolytic enzymes are biologically active substances that participate in the breakdown of unnecessary or damaged protein structures in the body. One of the particularly effective representatives of this class is Serrazime I – a proteolytic enzyme, with fibrinolytic and anti-inflammatory effects. Like serrapeptase, Serrazime I supports the breakdown of

fibrin – a protein involved in the formation of inflammatory plaques, adhesions and edema. Unlike serrapeptase, which is extracted from bacteria in the silkworm, Serrazime I is isolated by fermentation from edible mushrooms *Aspergillus oryzae* and *Aspergillus melleus*, which makes it suitable for vegetarians and people with sensitivity to animal products [41].

Bromelain is a plant-based natural proteolytic enzyme, extracted mainly from pineapple (*Ananas comosus*). [42]. Bromelain is a cysteine protease [43], which breaks down fibrin and improves normal blood and lymph flow, has powerful anti-inflammatory and analgesic properties, is used to reduce swelling and muscle pain, supports immunity and has antioxidant activity [44].

Bromelain inhibits cyclooxygenase and modulates prostaglandins and thromboxane [45]. Bromelain alone [46] and in combination with curcumin [47] can be used in the prevention of severe COVID-19, due to Curcumin exerts antioxidant activity [48].

Quercetin is a natural plant pigment (flavonoid) found in many fruits, vegetables, and grains (onions, apples, citrus, blueberries), known for its powerful antioxidant properties. Quercetin, as an anti-inflammatory compound is a potential treatment for severe inflammation in patients with COVID-19 [49]. From the experimental investigation a beneficial effect was reported when applying enzyme therapy using the product Fibrozime including the enzymes Serrazime and Bromelain) and antioxidant Quercetin. Against COVID-19 positive effect exerts combination of Bromelain, Quercetin and Vitamin C [50].

## CONCLUSION

Post-COVID fibrosis is a clinically significant and distinct group. It is characterized by younger patients and, most importantly, by the potential for partial regression. An individualized and multidisciplinary approach is needed. Therapeutic decisions should be based on the dynamics of the process (progression vs. regression), not on a static diagnosis.

#### Abbreviations

AIP	Acute Interstitial Pneumonia
ARDS	acute respiratory distress syndrome
CT	computer tomography
CTGF	connective tissue growth factor
ECM	extracellular matrix
IL	interleukines
IPF	Idiopathic Pulmonary Fibrosis
OP	organizing pneumonia
PDGF	platelet-derived growth factor
TGF- $\beta$	transforming growth factor-beta
TNF- $\alpha$	tumor necrosis factor-alpha

#### Additional information



**Conflict of interest**

The authors have declared that no competing interests exist.

**Ethical statements**

The authors declared that no clinical trials were used in the present study.

The authors declared that no experiments on humans or human tissues were performed for the present study.

The authors declared that no informed consent was obtained from the humans, donors or donors' representatives participating in the study.

The authors declared that no experiments on animals were performed for the present study.

The authors declared that no commercially available immortalized human and animal cell lines were used in the present study

**Funding:** No funding was reported.

**Author contributions:** All authors have contributed equally.

**Data availability:** All of the data that support the findings of this study are available in the main text or Supplementary Information.

**REFERENCES**

1. Zhao, M.; Wang, L.; Wang, M.; Zhou, S.; Lu, Y.; Cui, H.; Racanelli, A.C.; Zhang, L.; Ye, T.; Ding, B.; Zhang, B.; Yang, J.; Yao, Y. 2022. Targeting fibrosis: mechanisms and clinical trials. *Signal Transduction and Targeted Therapy*, 7(1):206. <https://doi.org/10.1038/s41392-022-01070-3>
2. Cheres, P.; Kim, S.J.; Tulasiram, S.; Kamp, D.W. 2013. Oxidative stress and pulmonary fibrosis. *Biochimica et Biophysica Acta: Molecular Basis of Disease*, 1832(7):1028–1040. <https://doi.org/10.1016/j.bbdis.2012.11.021>
3. Zou, M.; Zou, J.; Hu, X.; Zheng, W.; Zhang, M.; Cheng, Z. 2021. Latent transforming growth factor- $\beta$  binding protein-2 regulates lung fibroblast-to-myofibroblast differentiation in pulmonary fibrosis via NF- $\kappa$ B signaling. *Frontiers in Pharmacology*, 12:788714. <https://doi.org/10.3389/fphar.2021.788714>
4. Hosseinzadeh, A.K.; Javad-Moosavi, S.A.; Reiter, R.J.; Yarahmadi, R.; Ghaznavi, H.; Mehrzadi, S. 2018. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. *Expert Opinion on Therapeutic Targets*, 22(12):1049–1061. <https://doi.org/10.1080/14728222.2018.1541318>
5. Hu, H.H.; Chen, D.Q.; Wang, Y.N.; Feng, Y.L.; Cao, G.; Vaziri, N.D.; Zhao, Y.Y. 2018. New insights into TGF- $\beta$ /Smad signaling in tissue fibrosis. *Chemico-Biological Interactions*, 292:76–83. <https://doi.org/10.1016/j.cbi.2018.07.008>
6. Barnes, J.W.; Duncan, D.; Helton, S.; Hutcheson, S.; Kurundkar, D.; Logsdon, N.J.; Locy M.; Garth J.; Denson R.; Farver C.; Vo, H.T.; King, G.; Kentrup, D.; Faul, C.; Kulkarni, T.; De Andrade, J.A.; Yu, Z.; Matalon, S.; Thannickal, V.J.; Krick, S. 2019. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. *American Journal of Physiology-Lung Cellular and Molecular Physiology*, 317(1):L141–L154. <https://doi.org/10.1152/ajplung.00246.2018>
7. Frangogiannis, N.G. 2021. Cardiac fibrosis. *Cardiovascular Research*, 117(6):1450–1488. <https://doi.org/10.1093/cvr/cvaa324>
8. Yang, L. 2019. How acute kidney injury contributes to renal fibrosis. In: Liu, B.C.; Lan, H.Y.; Lv, L.L. (eds) *Renal Fibrosis: Mechanisms and Therapies*. *Advances in Experimental Medicine and Biology*, 1165:117–142. Springer, Singapore. [https://doi.org/10.1007/978-981-13-8871-2\\_7](https://doi.org/10.1007/978-981-13-8871-2_7)
9. Binatti, E.; Gerussi, A.; Barisani, D.; Invernizzi, P. 2022. The role of macrophages in liver fibrosis: new therapeutic opportunities. *International Journal of Molecular Sciences*, 23(12):6649. <https://doi.org/10.3390/ijms23126649>
10. Phan, T.H.G.; Paliogiannis, P.; Nasrallah, G.K.; Giordo, R.; Eid, A.H.; Fois, A.G.; Zinellu A.; Mangoni A.A.; Pintus G. 2021. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. *Cellular and Molecular Life Sciences*, 78(5):2031–2057. <https://doi.org/10.1007/s00018-020-03693-7>
11. Yue, Y.; Meng, K.; Pu, Y.; Zhang, X. 2017. Transforming growth factor beta (TGF- $\beta$ ) mediates cardiac fibrosis and induces diabetic cardiomyopathy. *Diabetes Research and Clinical Practice*, 133:124–130. <https://doi.org/10.1016/j.diabres.2017.08.018>
12. Meng, Q.; Bhandary, B.; Bhuiyan, M.S.; James, J.; Osinska, H.; Valiente-Alandi, I.; Shay-Winkler, K.; Gulick, J.; Molkentin, J.D.; Blaxall, B.C. 2018. Myofibroblast-specific TGF $\beta$  receptor II signaling in the fibrotic response to cardiac myosin binding protein C-induced cardiomyopathy. *Circulation Research*, 123(12):1285–1297. <https://doi.org/10.1161/CIRCRESAHA.118.313089>
13. Balakumar, P.; Sambathkumar, R.; Mahadevan, N.; Muhsinah, A.B.; Alsayari, A.; Venkateswaramurthy, N.; Jagadeesh, G. 2019. A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: Mechanisms and therapeutic implications. *Pharmacological Research*, 146:104314. <https://doi.org/10.1016/j.phrs.2019.104314>
14. Antar S.A.; Ashour N.A.; Marawan, M.E.; Al-Karmalawy, A.A. 2023. Fibrosis: types, effects, markers, mechanisms for disease progression, and

- its relation with oxidative stress, immunity, and inflammation. *International Journal of Molecular Sciences*, 24(4):4004. <https://doi.org/10.3390/ijms24044004>
15. Wang, J.; Lin, S.; Brown, J.M.; van Wagoner, D.; Fiocchi, C.; Rieder, F. 2021. Novel mechanisms and clinical trial endpoints in intestinal fibrosis. *Immunological Reviews*, 302(1):211–227. <https://doi.org/10.1111/imr.12974>
  16. Mahdy, M.A. 2019. Skeletal muscle fibrosis: an overview. *Cell and Tissue Research*, 375(3):575–588. <https://doi.org/10.1007/s00441-018-2955-2>
  17. Distler, J.H.; Györfi, A.H.; Ramanujam, M.; Whitfield, M.L.; Königshoff, M.; Lafyatis, R. 2019. Shared and distinct mechanisms of fibrosis. *Nature Reviews Rheumatology*, 15(12):705–730. <https://doi.org/10.1038/s41584-019-0322-7>
  18. Estornut, C.; Milara, J.; Bayarri, M.A.; Belhadj, N.; Cortijo, J. 2022. Targeting oxidative stress as a therapeutic approach for Idiopathic Pulmonary Fibrosis. *Frontiers in Pharmacology*, 12:794997. <https://doi.org/10.3389/fphar.2021.794997>
  19. Richeldi, L.; Davies, H.R.H.; Spagnolo, P.; Luppi, F.; Cochrane Airways Group. 1996. Corticosteroids for idiopathic pulmonary fibrosis. *Cochrane Database of Systematic Reviews*, 2. <https://doi.org/10.1002/14651858.CD002880>
  20. Richter, K.; Kietzmann, T. 2016. Reactive oxygen species and fibrosis: further evidence of a significant liaison. *Cell and Tissue Research*, 365(3):591–605. <https://doi.org/10.1007/s00441-016-2445-3>
  21. Day, B.J. 2008. Antioxidants as potential therapeutics for lung fibrosis. *Antioxidants Redox Signaling*, 10(2):355–370. <https://doi.org/10.1089/ars.2007.1916>
  22. Lee, J.C.; Kinniry, P.A.; Arguiri, E.; Serota, M.; Kanterakis, S.; Chatterjee, S.; Solomides, C.C.; Javvadi, P.; Koumenis, C.; Cengel, K.A.; Christofidou-Solomidou, M. 2010. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. *Radiation Research*, 173(5):590–601. <https://doi.org/10.1667/RR1522.1>
  23. Kandhare, A.D.; Mukherjee, A.; Ghosh, P.; Bodhankar, S.L. 2016. Efficacy of antioxidant in Idiopathic Pulmonary Fibrosis: a systematic review and meta-analysis. *EXCLI Journal*, 15:636–651. <https://doi.org/10.17179/excli2016-619>
  24. She, J.; Hou, D.; He, H.; Song, Y. 2020. Corticosteroids: a controversial therapy for coronavirus disease 2019. *Journal of Translational Internal Medicine*, 8(3):115–118. <https://doi.org/10.2478/jtim-2020-0019>
  25. Anan, K.; Kataoka, Y.; Ichikado, K.; Kawamura, K.; Johkoh, T.; Fujimoto, K.; Tobino K.; Tachikawa, R.; Ito, H.; Nakamura, T.; Kishaba, T.; Inomata, M.; Kamitani, T.; Yamazaki, H.; Ogawa, Y.; Yamamoto, Y. 2022. Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis. *Respiratory Research*, 23(1):291. <https://doi.org/10.1186/s12931-022-02195-3>
  26. Sethi, G.R.; Singhal, K.K. 2008. Pulmonary diseases and corticosteroids. *The Indian Journal of Pediatrics*, 75(10):1045–1056. <https://doi.org/10.1007/s12098-008-0209-0>
  27. Prescott, H.C.; Rice, T.W. 2020. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. *JAMA*. <https://doi.org/10.1001/jama.2020.16747>
  28. Chang, X.; Li, S.; Fu, Y.; Dang, H.; Liu, C. 2022. Safety and efficacy of corticosteroids in ARDS patients: a systematic review and meta-analysis of RCT data. *Respiratory Research*. 23(1): 301. <https://doi.org/10.1186/s12931-022-02186-4>
  29. Meduri, G.U.; Siemieniuk, R.A.C.; Ness, R.A., Seyler, S.J. 2018. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. *Journal of Intensive Care*, 6(1):53. <https://doi.org/10.1186/s40560-018-0321-9>
  30. Melani, A.S.; Croce, S.; Cassai, L.; Montuori, G.; Fabbri, G.; Messina, M.; Viani, M.; Bargagli, E. 2023. Systemic corticosteroids for treating respiratory diseases: less is better, but... when and how is it possible in real life?. *Pulmonary Therapy*, 9(3):329–344. <https://doi.org/10.1007/s41030-023-00227-x>
  31. Lin, P.; Zhao, Y.; Li, X.; Jiang, F.; Liang, Z. 2021. Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomised clinical trials with trial sequential analysis. *Critical Care*, 25(1):122. <https://doi.org/10.1186/s13054-021-03546-0>
  32. Chappell, L.; Horby, P.; Lim, W.S., Emberson, J.R.; Mafham, M.; Bell, J. L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Green, C.; Felton, T.; Chadwick, D.; Rege, K.; Fegan, C.; Faust, S.N.; Landray, M.J. 2021. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *The New England Journal of Medicine*, 384(8):693–704. <https://doi.org/10.1056/NEJMoa2021436>
  33. Salvi, S.S.; Ghorpade, D.; Dhoori, S.; Dhar, R.; Dumra, H.; Chhajed, P.N.; Bhattacharya, P.; Rajan, S.; Talwar, D.; Christopher, D.J.; Mohan, M.; Udwadia, Z. 2022. Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group. *Lung India*, 39(2):177–186. [https://doi.org/10.4103/lungindia.lungindia\\_659\\_21](https://doi.org/10.4103/lungindia.lungindia_659_21)
  34. Mohammadi, A.; Balan, I.; Yadav, S.; Matos, W.F., Kharawala, A., Gaddam, M., Ricaldez N.S.; Koneru S.C.; Suddapalli, S.K.; Marzban, S. 2022.

- Post-COVID-19 pulmonary fibrosis. *Cureus*, 14(3):e22770. <https://doi.org/10.7759/cureus.22770>
35. Choudhary, R.; Kumar, A.; Ali, O.; Pervez, A. 2022. Effectiveness and safety of Pirfenidone and Nintedanib for pulmonary fibrosis in COVID-19-induced severe pneumonia: an interventional study. *Cureus*, 14(9):e29435. <https://doi.org/10.7759/cureus.29435>
36. Wollin, L.; Wex, E.; Pautsch, A.; Schnapp, G.; Hostettler, K.E.; Stowasser, S.; Kolb, M. 2015. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. *European Respiratory Journal*, 45(5):1434–1445. <https://doi.org/10.1183/09031936.00174914>
37. Seifirad, S. 2020. Pirfenidone: a novel hypothetical treatment for COVID-19. *Medical Hypotheses*, 144:110005. <https://doi.org/10.1016/j.mehy.2020.110005>
38. Azuma, A.; Nukiwa, T.; Tsuboi, E.; Suga, M.; Abe, S.; Nakata, K.; Taguchi, Y.; Nagai, S.; Itoh, H.; Ohi, M.; Sato, A.; Kudoh, S. 2005. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, 171(9):1040–1047. <https://doi.org/10.1164/rccm.200404-571OC>
39. Hamidi, S.H.; Kadamboor-Veethil, S.; Hamidi, S.H. 2021. Role of pirfenidone in TGF- $\beta$  pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective. *Pharmacological Reports*, 73(3):712–727. <https://doi.org/10.1007/s43440-021-00255-x>
40. Al-Kuraishy, H.M.; Batiha, G.E.S.; Faidah, H.; Al-Gareeb, A.I.; Saad, H.M.; Simal-Gandara, J. 2022. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. *Inflammopharmacology*, 30(6):2017–2026. <https://doi.org/10.1007/s10787-022-01027-6>
41. Bratovic, A.J.A.S. 2020. Antioxidant enzymes and their role in preventing cell damage. *Acta Scientific Nutritional Health*, 4(3):01–07. <https://doi.org/10.31080/ASNH.2020.04.0659>
42. Taussig, S.J.; Batkin, S. 1988. Bromelain, the enzyme complex of pineapple (*Ananas comosus*) and its clinical application. An update. *Journal of Ethnopharmacology*, 22(2):191–203. [https://doi.org/10.1016/0378-8741\(88\)90127-4](https://doi.org/10.1016/0378-8741(88)90127-4)
43. Rowan, A.D.; Buttle, D.J.; Barrett, A.J. 1990. The cysteine proteinases of the pineapple plant. *Biochemical Journal*, 266(3):869. MID: 2327970 PMID: PMC1131219
44. Hikisz, P.; Bernasinska-Slomczewska, J. 2021. Beneficial properties of Bromelain. *Nutrients*, 13(12):4313. <https://doi.org/10.3390/nu13124313>
45. Pavan, R.; Jain, S.; Shraddha; Kumar, A. 2012. Properties and therapeutic application of bromelain: a review. *Biotechnology Research International*, 1:976203. <https://doi.org/10.1155/2012/976203>
46. Kumar, V.; Garg, V.; Dureja, H. 2024. Role of Pineapple and its Bioactive Compound Bromelain in COVID 19. *Current Nutrition & Food Science*, 20(3):305–316. <https://doi.org/10.2174/1573401319666230418104554>
47. Kritis, P.; Karampela, I.; Kokoris, S.; Dalamaga, M. 2020. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19. *Metabolism Open*, 8:100066. <https://doi.org/10.1016/j.metop.2020.100066>
48. Soni, V.K.; Mehta, A.; Ratre, Y.K.; Tiwari, A.K.; Amit, A.; Singh, R.P.; Sonkar, S.C.; Chaturvedi, N.; Shukla, D.; Vishvakarma, N.K. 2020. Curcumin, a traditional spice component, can hold the promise against COVID-19? *European Journal of Pharmacology*, 886:173551. <https://doi.org/10.1016/j.ejphar.2020.173551>
49. Saeedi-Boroujeni, A.; Mahmoudian-Sani, M.R. 2021. Anti-inflammatory potential of Quercetin in COVID-19 treatment. *Journal of Inflammation*, 18(1):3. <https://doi.org/10.1186/s12950-021-00268-6>
50. Kamel, A.; Abdelseed, H.; Albalawi, Y.; Aslsalameen, E.; Almutairi, Y.; Alkattan, A. 2020. Evaluation of the effect of zinc, quercetin, bromelain and vitamin C on COVID-19 patients. *MedRxiv*, 2020:12. <https://doi.org/10.1101/2020.12.22.20245993>